#capricor

2 briefings

FDA Hits Pause on Capricor's Duchenne Cell Therapy — Again

Aug 25, 2026, 10:28 PM

Bad News Week for Biotech: FDA Doubts, a 60% Stock Drop and a Sarepta Shakeup

Jul 27, 2026, 11:06 PM